{"schema_version":"secwatch.filing_event.v1","accession":"0001159036-23-000037","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.079194+00:00","generated_at":"2026-06-15T08:14:50.294034+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Halozyme Q1 revenue up 38% to $162M; GAAP EPS $0.29; reiterates 2023 guidance","bullets":["Revenue of $162.1M (+38% YoY); royalty revenue $99.6M (+43% YoY).","GAAP diluted EPS $0.29; non-GAAP diluted EPS $0.47 (flat YoY).","Q1 net income $39.6M vs $60.1M in Q1 2022; EBITDA $74.3M.","Reiterates 2023 guidance: total revenue $815-845M, non-GAAP EPS $2.50-$2.65.","Repurchased 4.2M shares for $150M in Q1; $275.6M cash end of quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0001159036-23-000037","json":"https://secwatch.observer/filing/0001159036-23-000037.json","markdown":"https://secwatch.observer/filing/0001159036-23-000037.md","text":"https://secwatch.observer/filing/0001159036-23-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000115903623000037/0001159036-23-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000115903623000037/halo-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T08:14:50.294034+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e226ad080642e90bbfc6708b2beef3a37d18b292","claim":"HALOZYME THERAPEUTICS, INC. reported the first quarter ended March 31, 2023 results: revenue $162.1 million, net income $39.6 million, EPS $0.29. Guidance reaffirmed.","evidence_excerpt":"any general incorporation language in such filing. --- EX-99.1 (EX-99.1) --- HALOZYME REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATING RESULTS Revenue Increased 38% YOY to $162.1 million; GAAP Diluted Earnings per Share of $0.29 and Non-GAAP Diluted Earnings per Share of $0.47 1 Royalty Revenue Increased 43% YOY to $99.6 million Reiterating 2023 Revenue Guidance","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903623000037/0001159036-23-000037-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$162.1 million"},{"label":"Net income","value":"$39.6 million"},{"label":"EPS","value":"$0.29"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}